Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

NCT05740215 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

NCT04708210 ·Status: UNKNOWN ·Phase: PHASE1

Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC

NCT04153097 ·Status: UNKNOWN

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

NCT04945200 ·Status: UNKNOWN

IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.

NCT04912466 ·Status: COMPLETED ·Phase: PHASE1

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer

NCT01592422 ·Status: UNKNOWN ·Phase: PHASE2

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NCT05118334 ·Status: COMPLETED ·Phase: PHASE1

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT05949606 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of IBI323 in Patients With Advanced Malignancies

NCT04916119 ·Status: UNKNOWN ·Phase: PHASE1

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

NCT05295212 ·Status: RECRUITING ·Phase: PHASE2

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

NCT03195491 ·Status: COMPLETED ·Phase: PHASE3

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05636215 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06198426 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

NCT06532591 ·Status: RECRUITING ·Phase: PHASE2

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

NCT04611321 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Phase I/Ib Multiple Ascending Dose Study in China

NCT03523390 ·Status: COMPLETED ·Phase: PHASE1

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

NCT05940532 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

NCT05504278 ·Status: RECRUITING ·Phase: PHASE1

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

NCT04328831 ·Status: COMPLETED ·Phase: PHASE1

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

NCT03545971 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT05923008 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

NCT05055908 ·Status: RECRUITING ·Phase: PHASE3

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

NCT04189094 ·Status: UNKNOWN ·Phase: PHASE2

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT05956587 ·Status: RECRUITING ·Phase: PHASE2

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NCT04945421 ·Status: COMPLETED ·Phase: PHASE1